Amgen Disagrees With FDA Proposal To Withdraw TAVNEOS From U.S. Market; Submitted Data And Analyses To FDA To Request Hearing On TAVNEOS
https://www.amgen.com/newsroom/company-statements/amgen-statement-on-fda-data-submission-for-tavneos?_gl=1*p4mfe*_up*MQ..*_ga*MjAxMjQ2Mjc4My4xNzg0ODk1MTYx*_ga_CBMSV0J9VL*czE3ODQ4OTUxNjEkbzEkZzEkdDE3ODQ4OTUxODMkajM4JGwwJG
Amgen's medicine TAVNEOS might get removed from the U.S., but the company disagrees and sent extra information to the FDA asking for a chance to explain why it should stay. When a company fights back with new data, it shows they believe in their product and think they can prove it's safe.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.